Asset Details
Do you wish to reserve the book?
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
Do you wish to request the book?
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
2007
Overview
Type 1 cytokines are overexpressed in psoriatic plaques. This trial evaluated a monoclonal antibody against interleukin-12 and interleukin-23 in patients with psoriasis. Response rates at 12 weeks were significantly higher in patients treated with interleukin-12/23 monoclonal antibody than in those treated with placebo. Four percent of patients who received interleukin-12/23 monoclonal antibody and 1% of those who received placebo had serious adverse events. Larger studies of longer duration are needed to assess the effectiveness and safety of interleukin-12/23 monoclonal antibody for psoriasis.
In patients with psoriasis, response rates at 12 weeks were significantly higher in those treated with interleukin-12/23 monoclonal antibody than in those treated with placebo.
Psoriasis is a chronic inflammatory skin disorder affecting 2 to 3% of the world's population.
1
,
2
Psoriasis affects the physical and emotional well-being of patients, and its effect on quality of life is similar to that seen with other major medical diseases.
3
Significant unmet need remains for safe, highly effective, and convenient treatments. Aberrant type 1 immune responses have been linked to the pathogenesis of psoriasis,
4
–
7
and cytokines that elicit these immune responses (e.g., interleukin-12 and interleukin-23) may represent appropriate therapeutic targets.
8
Interleukin-12 p40 is overexpressed in psoriasis plaques,
9
and preclinical studies implicate this cytokine in the pathogenesis of . . .
Publisher
Massachusetts Medical Society
